Neuroprotective agents refer to compounds and drugs that are used to protect neurons and other cells of the nervous system from damage and diseases. The concept of neuroprotection was introduced in the 1980s and has since become an increasingly important field of research in neuroscience. Neuroprotection is a complex process that involves a number of different factors, such as the prevention of neurotoxin accumulation, the promotion of neuronal survival or regeneration, the inhibition of apoptosis, and the control of inflammatory cascades. Neuroprotection is thought to be triggered by a variety of different stimuli, including oxidative stress, glutamate excitotoxicity, and calcium dysregulation. One approach to protection of the nervous system is to target the neurotoxins, such as those secreted by activated glia. Inhibition of excitotoxicity can be reached by both antagonizing glutamate receptors or blocking its receptors from binding the agonists. Many drugs have been developed that target neurological receptors, reducing the influx of calcium and reducing intracellular calcium levels. Another approach is to target cell survival and regenerative pathways. Neurotrophic factors such as nerve growth factor (NGF) are able to promote neurogenesis and neuronal survival. In addition, antioxidants are proposed to reduce oxidative damage and perceived age-related diseases of the CNS. The use of both natural and synthetic compounds, such as vitamins, minerals, plant extracts, and herbal derivatives, has been proposed in the treatment of neurodegenerative diseases. It is important to understand that not all treatments are equal and that careful selection is necessary to find an effective and safe neuroprotective agent. It is also important to consider potential side effects of any of the agents and whether they will hamper the therapeutic effect. Ultimately, it is up to the patient and the healthcare provider to decide which neuroprotective agent is best for the given situation.
Title : Scalp acupuncture with functional electrical stimulation for the treatment children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy, Australia
Title : A structure-based strategy to target pathogenic α-synuclein in Parkinson’s disease
Salvador Ventura, Autonomous University of Barcelona, Spain
Title : Rabies: Challenges in taming the beast
Alan C Jackson, University of Calgary, Canada
Title : Designing and managing intelligent and ethical transformed health and social care ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Understanding Alzheimer's disease biomarkers across diverse populations - Opportunities and Insights for novel prevision medicine approaches
Sid O Bryant, Texas College of Osteopathic Medicine and University of North Texas Health Science Center Fort Worth, United States